Health Ventures’ (OHV) is an early stage company, which has developed a
proprietary, recombinant, genetic toxoid vaccine candidate against epsilon
toxin (ETX), which can be cultured in E.coli, as a treatment for both animals
and humans. The vaccine has been successfully trialed in mice, rabbits
and sheep and the next step is to seek approval for and then to carry out a
Phase 1 trial.
ETX is produced from a common bacteria Clostridium perfringens Types B/D and
causes a fatal disease, enterotoxaemia, principally in sheep and goats.
Over the past 7 years, ETX has also been implicated as the trigger for
Multiple Sclerosis (MS), which affects about 2.5 million people worldwide and
for which there is currently no cure or human vaccine. Significant
levels of ETX, antibodies to ETX and the relevant bacterial strains have all
been found in MS patients and to a lesser extent in controls.
OHV is seeking a commercial partner(s) either to licence or enter into a
joint venture(s) in order to take this project forward.